维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02561 维昇药业-B

已收盘 07-02 16:08:21

25.000

+5.020

+25.13%

最高25.800	最低19.130	成交量16.89万
今开20.280	昨收19.980	日振幅33.38%
总市值28.50亿	流通市值28.50亿	总股本1.14亿
成交额391.07万	换手率0.15%	流通股本1.14亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02561","market":"HK","secType":"STK","nameCN":"维昇药业-B","latestPrice":25,"timestamp":1782979701008,"preClose":19.98,"halted":0,"volume":168900,"delay":0,"changeRate":0.25125125125125125,"floatShares":113999999,"shares":113999999,"eps":-2.44,"marketStatus":"已收盘","change":5.02,"latestTime":"07-02 16:08:21","open":20.28,"high":25.8,"low":19.13,"amount":3910718,"amplitude":0.333834,"askPrice":25,"askSize":800,"bidPrice":24.2,"bidSize":5300,"shortable":3,"etf":0,"ttmEps":-2.466,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783042200000},"marketStatusCode":5,"adr":0,"listingDate":1742486400000,"exchange":"SEHK","adjPreClose":19.98,"openAndCloseTimeList":[[1782955800000,1782964800000],[1782968400000,1782979200000]],"volumeRatio":30.487364,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02561","defaultTab":"news","newsList":[{"id":"2648090055","title":"维升药业-B（02561）盘中涨近30%背后：市场聚焦核心产品放量，维臻高®商业化再提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2648090055","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648090055?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:32","pubTimestamp":1782988323,"startTime":"0","endTime":"0","summary":"7月2日，港股医药板块全线爆发，其中维升药业-B盘中放量飙升近30%，领跑整个创新药板块。截至当日收市，维升药业全日涨幅达25.13%，收至25港元，表现十分亮眼。今年1月，公司核心产品长效生长激素隆培生长激素正式获批上市，适用于3岁及以上儿童、青少年生长激素缺乏症的治疗，也意味着维升药业开始进入商业化兑现周期。2026年维升药业正以进口方式进行商业化，计划2028年实现技术转移及本地化生产。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462440.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648573106","title":"港股异动 | 维升药业-B(02561)早盘涨超15% 公司近期与镁信健康达成项目合作 探索多元支付新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2648573106","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648573106?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:31","pubTimestamp":1782959502,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，维升药业-B早盘涨超15%，截至发稿，涨15.22%，报23.02港元，成交额148.2万港元。消息面上，维升药业近日宣布，与中国领军医药多元支付平台镁信健康达成项目合作。双方将充分发挥各自在创新疗法与健康服务领域的资源优势，共同探索提升内分泌疾病创新疗法可及性与可支付性的多元路径，助力中国患者更便捷地获益于全球前沿的治疗方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462152.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK4585","BK1161","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648573101","title":"港股异动 | 维升药业-B(02561.HK)早盘涨超15% 公司近期与镁信健康达成项目合作 探索多元支付新模式","url":"https://stock-news.laohu8.com/highlight/detail?id=2648573101","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648573101?lang=zh_cn&edition=full","pubTime":"2026-07-02 10:31","pubTimestamp":1782959502,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647379633","title":"维升药业-B(02561)6月29日斥资8.46万港元回购4300股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647379633","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647379633?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:59","pubTimestamp":1782734357,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年6月29日，该公司斥资8.46万港元回购4300股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460567.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122246339","title":"维昇药业-B 6月29日回购约0.43万股，耗资约8.46万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1122246339","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122246339?lang=zh_cn&edition=full","pubTime":"2026-06-29 19:57","pubTimestamp":1782734226,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年6月29日公布翌日披露报表，披露6月29日于香港联合交易所场内回购股份的具体信息。本次回购股份数量为4,300股，占回购前已发行股本约0.004%。回购价格每股介乎港币19.18元至港币20元，涉及总金额84,641港元，折合约8.46万港元。回购完成后，公司已发行股本为113,753,364股，库藏股数量增加至173,500股，总发行股本维持在113,926,864股。根据公告，公司确认已遵守香港联交所证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维昇药业-B 6月29日回购约0.43万股，耗资约8.46万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646357787","title":"维升药业-B(02561)委任Roy Paul Khoury、Sherrie Lynn Glass及Michael J. Chang为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2646357787","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646357787?lang=zh_cn&edition=full","pubTime":"2026-06-26 20:48","pubTimestamp":1782478120,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，经股东于股东周年大会上批准后，委任Roy Paul Khoury先生、Sherrie Lynn Glass女士及Michael J. Chang先生为非执行董事已自2026年6月26日起生效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459735.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167346466","title":"维昇药业-B6月23日回购0.40万股股份，涉资约7.68万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167346466","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167346466?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:15","pubTimestamp":1782216957,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年6月23日发布翌日披露报表，宣布于当日于香港联交所场内回购0.40万股普通股，占紧接回购前已发行股本约0.004%。该批股份每股回购价格介乎每股19.17港元至19.24港元，总金额约7.68万港元。回购授权于2025年6月27日获股东大会通过，公司依照授权可回购股份总数为11,392,686股，截至目前已在香港联交所或其他证券交易所合计回购169,200股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维昇药业-B6月23日回购0.40万股股份，涉资约7.68万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645783632","title":"维升药业-B(02561)6月23日斥资约7.68万港元回购4000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645783632","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645783632?lang=zh_cn&edition=full","pubTime":"2026-06-23 20:13","pubTimestamp":1782216790,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年6月23日该公司斥资约7.68万港元回购4000股，回购价格为每股19.17至19.24港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188480611","title":"维昇药业-B：6月22日回购4,800股，涉资约9.50万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188480611","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188480611?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:06","pubTimestamp":1782122805,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年6月22日发布公告称，公司当日通过香港联交所场内回购普通股4,800股，占此前已发行股本约0.004%，回购价格介乎每股19.80港元至19.81港元，总成交金额约9.50万港元。回购完成后，公司已发行股本为113,761,664股，库存股数量为165,200股。公告显示，该次股份回购依据2025年6月27日通过的购回授权进行。根据授权，公司可回购总数为11,392,686股，截至目前已累计回购165,200股；占购回授权通过时已发行股本的0.14501%。本公告由执行董事卢安邦签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维昇药业-B：6月22日回购4,800股，涉资约9.50万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645946025","title":"维升药业-B(02561)6月22日斥资9.5万港元回购4800股","url":"https://stock-news.laohu8.com/highlight/detail?id=2645946025","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645946025?lang=zh_cn&edition=full","pubTime":"2026-06-22 18:06","pubTimestamp":1782122785,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年6月22日斥资9.5万港元回购4800股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1456990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136859785","title":"维昇药业-B 6月18日回购约0.73万股，耗资约14.26万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1136859785","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136859785?lang=zh_cn&edition=full","pubTime":"2026-06-18 17:55","pubTimestamp":1781776559,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年6月18日发布翌日披露报表，公告显示，公司于当日在香港联交所场内回购股份0.73万股，占当日现有已发行股份约0.006%。回购价格介乎每股19.41港元至20.10港元，合计耗资约14.26万港元。此次回购的股份将作库藏用途。根据公告，截至2026年6月18日收盘，公司已发行股份总数为113,926,864股，其中流通股份113,766,464股，存于库藏的股份为160,400股。公司指，于2025年6月27日通过的股份回购授权可回购最多11,392,686股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"维昇药业-B 6月18日回购约0.73万股，耗资约14.26万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644743859","title":"维升药业-B(02561)6月17日斥资9.1万港元回购4700股","url":"https://stock-news.laohu8.com/highlight/detail?id=2644743859","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644743859?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:16","pubTimestamp":1781694995,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年6月17日斥资9.1万港元回购4700股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144103752","title":"维昇药业-B回购4700股股份，总额约9.13万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144103752","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144103752?lang=zh_cn&edition=full","pubTime":"2026-06-17 19:16","pubTimestamp":1781694978,"startTime":"0","endTime":"0","summary":"2026年6月17日，维昇药业-B发布翌日披露报表。公告显示，公司于当日在香港联交所场内回购普通股合共4700股，占回购前公司已发行股本约0.004%。回购价格介乎每股19.35港元至19.67港元，总金额约为91,298港元。本次回购完成后，公司已发行股本变为113,773,764股，库藏股增至153,100股，合计股数仍为113,926,864股。维昇药业-B回购授权于2025年6月27日获股东大会通过，可回购股份总数为11,392,686股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维昇药业-B回购4700股股份，总额约9.13万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180836836","title":"维昇药业-B：6月16日回购7700股股份，涉资约14.96万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1180836836","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180836836?lang=zh_cn&edition=full","pubTime":"2026-06-16 18:16","pubTimestamp":1781604970,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年6月16日发布翌日披露报表称，公司当日于香港联交所场内回购7700股股份，约占该次回购前已发行股本总数的0.007%。回购股份的最高价为每股19.71港元、最低价为19.31港元，合计支付约14.96万港元。公告显示，此次回购完成后，公司已发行股份由2026年6月15日的113,786,164股减至113,778,464股，库藏股数由140,700股增至148,400股，公司已发行股本总数则保持在113,926,864股不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"维昇药业-B：6月16日回购7700股股份，涉资约14.96万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643065203","title":"维升药业-B(02561)6月15日斥资约29.26万港元回购1.49万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2643065203","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643065203?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:27","pubTimestamp":1781526433,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年6月15日该公司斥资约29.26万港元回购1.49万股，回购价格为每股19.50至19.94港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454602.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02561","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145827083","title":"维昇药业-B：6月15日回购14,900股，耗资约29.26万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1145827083","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145827083?lang=zh_cn&edition=full","pubTime":"2026-06-15 20:26","pubTimestamp":1781526410,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年6月15日发布公告，披露当日于香港联交所场内回购14,900股普通股，占该公司现有已发行股本约0.013%。此次回购价格区间为每股19.50港元至19.94港元，总金额约29.26万港元。回购后，公司最新已发行股本总数仍为113,926,864股，其中已发行股份为113,786,164股，库存股份数为140,700股。公告显示，回购授权于2025年6月27日获股东大会通过，授权公司可回购股份总数为11,392,686股，截至目前已累计回购140,700股，约占授权时已发行股本的0.1235%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维昇药业-B：6月15日回购14,900股，耗资约29.26万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100659232","title":"维昇药业-B回购5900股股份，耗资约11.79万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1100659232","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100659232?lang=zh_cn&edition=full","pubTime":"2026-06-12 18:47","pubTimestamp":1781261233,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年6月12日发布公告，披露当日通过香港联交所场内回购公司股份，回购数量为5900股，占当日前已发行股本约0.005%，每股回购价介乎19.91港元至20.06港元，合计支付约11.79万港元。本次回购完成后，维昇药业-B的已发行股份总数维持113,926,864股不变，惟其中不包括库藏股的已发行股份数降至113,801,064股，而库藏股数则增至125,800股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维昇药业-B回购5900股股份，耗资约11.79万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101132470","title":"维昇药业-B：6月11日回购12,100股，耗资约24.27万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101132470","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101132470?lang=zh_cn&edition=full","pubTime":"2026-06-11 18:11","pubTimestamp":1781172710,"startTime":"0","endTime":"0","summary":"维昇药业-B2026年6月11日公告披露，公司于当日于香港联交所场内回购12,100股普通股，占回购前公司已发行股本约0.011%。回购股份的每股价格介乎19.77港元至20.40港元，合计付出约24.27万港元。回购完成后，公司已发行股本为113,806,964股，库藏股增至119,900股，总股本仍为113,926,864股。根据2025年6月27日通过的回购授权，公司可回购股份总数为11,392,686股。公司确认已严格遵守香港联交所证券上市规则及相关法律法规完成本次回购事项。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维昇药业-B：6月11日回购12,100股，耗资约24.27万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119697634","title":"维昇药业-B回购10,400股，耗资约20.72万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119697634","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119697634?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:42","pubTimestamp":1781088162,"startTime":"0","endTime":"0","summary":"维昇药业-B于2026年6月10日发布公告称，公司当日回购普通股10,400股，占当日回购前已发行股本的约0.009%。本次回购价格区间为每股19.71港元至20.28港元，合计付出约20.72万港元。回购完成后，公司持有库藏股107,800股，已发行股本为113,819,064股，合计股份总数为113,926,864股。据公告显示，本次回购已于2025年6月27日的股东大会上获批，公司可于购回授权有效期内回购最多11,392,686股。截至目前，根据该项授权已累计在交易所购回107,800股，占授出当日已发行股本数目的约0.09462%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"维昇药业-B回购10,400股，耗资约20.72万港元","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02561"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642440437","title":"维升药业-B(02561)6月10日斥资20.72万港元回购1.04万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642440437","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642440437?lang=zh_cn&edition=full","pubTime":"2026-06-10 18:39","pubTimestamp":1781087967,"startTime":"0","endTime":"0","summary":"智通财经APP讯，维升药业-B(02561)发布公告，于2026年6月10日斥资20.72万港元回购1.04万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02561"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.visenpharma.com","stockEarnings":[{"period":"1week","weight":0.0385},{"period":"1month","weight":-0.129},{"period":"3month","weight":-0.2002},{"period":"6month","weight":-0.3909},{"period":"1year","weight":-0.5589},{"period":"ytd","weight":-0.3909}],"compareEarnings":[{"period":"1week","weight":-0.0195},{"period":"1month","weight":-0.0914},{"period":"3month","weight":-0.0954},{"period":"6month","weight":-0.1073},{"period":"1year","weight":-0.0495},{"period":"ytd","weight":-0.1073}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"维昇药业是一家主要从事开发并商业化颠覆式内分泌疗法的投资控股公司。该公司的主要在研产品包括隆培促生长素、那韦培肽和帕罗培特立帕肽。隆培促生長素用于治疗3至17岁儿童生长激素缺乏症患者。那韦培肽是一款用于治疗2至10岁软骨发育不全儿童患者的疾病修复疗法。帕罗培特立帕肽是一款用于治疗成人甲状旁腺功能减退症的治疗方法。该公司处于研发后期、产品接近商业化。","exchange":"SEHK","name":"维昇药业-B","nameEN":"VISEN PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"维昇药业-B,02561,维昇药业-B股票,维昇药业-B股票老虎,维昇药业-B股票老虎国际,维昇药业-B行情,维昇药业-B股票行情,维昇药业-B股价,维昇药业-B股市,维昇药业-B股票价格,维昇药业-B股票交易,维昇药业-B股票购买,维昇药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"维昇药业-B(02561)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供维昇药业-B(02561)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}